event on
Leuven,
The event, organized in key cities such as
Pascal Ghoson, CEO of
For more information on the event, please visit their website.
About Oxurion Oxurion
(Euronext Brussels: OXUR) is committed to the development of next-generation standard ophthalmic therapies for the treatment of retinal diseases.
Important information on forward-looking statements
Certain statements contained in this press release may be considered as “forward-looking". These forward looking statements are based on current expectations and are therefore subject to various risks and uncertainties. The company therefore cannot guarantee that these forward-looking statements will materialise and does not undertake to update or revise them, whether as a result of new information, future events or for any other reason. Additional information on the risks and uncertainties affecting the company and other factors that could cause actual results to differ materially from forward-looking statements is included in the company's annual report. This press release does not constitute an offer or an invitation to sell or buy securities or assets of
Contacts :
Pascal Ghoson pascal.ghoson@oxurion.com |
Attachments
- EN
- FR
Source:
2024 GlobeNewswire, Inc., source